Randy Sweis is an Oncology physician affiliated with University of Illinois Chicago. OpenAlex indexes 322 publications with 4,571 citations (h-index 30).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5841 S Maryland Ave
Chicago, IL 606371443
Telephone
888-824-0200Registry record last updated 24 Oct 2022.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eisai Inc.Program year20252 payments
- Eisai Co., Ltd.Program year20251 payment
- Eli Lilly and CompanyProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
59.7%Cytochrome P450 17A1 Inhibitor27.7%Abiraterone Acetate100%Part D<11 patientsKinase inhibitor24.7%Cabometyx68%Lenvima32%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
33.8%Corticosteroid33.8%Prednisone100%Part D≥16 patientsNervous system
6.5%Phenothiazine6.5%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2018–2021 per NIH RePORTER. The latest:
- Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer
University of Chicago
FY2021$212,669K08CA234392 - Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer
University of Chicago
FY2020$212,669K08CA234392 - Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer
University of Chicago
FY2019$212,669K08CA234392
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Journal of the National Comprehensive Cancer Network
2024 - Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Jerry Krishnan, MD
University of Illinois Chicago
Victor Gordeuk, MD
University of Illinois Chicago
Richard Penn, MD
University of Illinois Chicago
William Mieler, MD
University of Illinois Chicago
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”